The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1060-1066

  Cottrell, Tricia R ^a   Wise, Robert A ^a   Wigley, Fredrick M ^a   Boin, Francesco ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; SCL 70 ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SCLERODERMA; SKIN DISEASE; SKIN FIBROSIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; PULMONARY FIBROSIS; SYSTEMIC SCLEROSIS;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; LUNG DISEASES; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84899990932     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202849     Document Type: Article

References (48)

1. Boin F, Wigley FM. Clinical features and treatment of scleroderma. In: Firestein GS, Budd RC, Gabriel SE, et al. Kelley's textbook of rheumatology. 9th edn. Philadelphia, PA: Elsevier, 2012: 1366-403.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66: 940-4. (Pubitemid 46999798)
3. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23: 581-90.
4. Barnett AJ. Classification of systemic sclerosis (scleroderma). In: Black CM, Myers AR. Current topics in rheumatology: systemic sclerosis (scleroderma). New York, NY: Gower Medical Publishing, 1985:18.
5. Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13: 911-16. (Pubitemid 17203925)
6. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15: 202-5. (Pubitemid 18073738)
7. Nishimagi E, Kawaguchi Y, Tanaka E, et al. Classification of systemic sclerosis in the Japanese population based on rapid progression of skin thickening. Mod Rheumatol 2004;14: 216-21. (Pubitemid 39206665)
8. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988;15: 276-83. (Pubitemid 18073752)
9. Ferri C, Bernini L, Cecchetti R, et al. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol 1991;18: 1826-32.
10. Vayssairat M, Baudot N, Abuaf N, et al. Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations. Clin Rheumatol 1992;11: 356-63.
11. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002;81: 154-67. (Pubitemid 34218570)
12. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 2005;44: 1212-16. (Pubitemid 41487952)
13. Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. J Rheumatol 2007;34: 1855-63. (Pubitemid 350067646)
14. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66: 754-63. (Pubitemid 46846694)
15. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29: 515-24. (Pubitemid 16118701)
16. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118: 2-10. (Pubitemid 40082450)
17. Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma: demographic, clinical and serologic features and survival in forty-eight patients. Arthritis Rheum 2000;43: 444-51. (Pubitemid 30395756)
18. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serologic features and survival in 1, 012 Italian patients. Medicine 2002;81: 139-53. (Pubitemid 34218569)
19. Masi AT. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988;15: 894-8.
20. Baron M, Sutton E, Hudson M, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008;67: 644-50. (Pubitemid 351571928)
21. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37: 1283-9. (Pubitemid 24320744)
22. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997;24: 81-5. (Pubitemid 27059862)
23. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22: 1281-5.
24. Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26: 2159-67. (Pubitemid 29487010)
25. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61: 554-8. (Pubitemid 34539104)
26. Knudson RJ, Kaltenborn WT, Knudson DE, et al. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987;135: 805-11. (Pubitemid 17055505)
27. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144: 1202-18.
28. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159: 179-87. (Pubitemid 29036522)
29. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004;43: 461-6. (Pubitemid 38489363)
30. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004;22:S5-13.
31. Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 2004;10:CR615-21. (Pubitemid 39546036)
32. Hudson M, Fritzler MJ, Baron M; Canadian Scleroderma Research Group (CSRG). Systemic sclerosis: establishing diagnostic criteria. Medicine 2010;89: 159-65.
33. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37: 750-5.
34. Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010;103: 109-15.
35. Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010;35: 112-17.
36. Clements PJ, Roth MD, Elashoff R, et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007;66: 1641-7. (Pubitemid 350205454)
37. Kane GC, Varga J, Conant EF, et al. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 1996;90: 223-30. (Pubitemid 26130211)
38. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62: 146-50. (Pubitemid 36135390)
39. Hanitsch LG, Burmester GR, Witt C, et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations-an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford) 2009;48: 70-3.
40. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic and behavioral factors. Arthritis Rheum 2007;57: 318-26. (Pubitemid 47164096)
41. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48: 2246-55. (Pubitemid 36959206)
42. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40: 734-42. (Pubitemid 27157581)
43. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic and immunogenetic determinants. Semin Arthritis Rheum 2001;30: 332-46. (Pubitemid 32298859)
44. Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
45. Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55: 598-602. (Pubitemid 44289880)
46. Hasegawa M, Asano Y, Endo H, et al. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study. Rheumatology (Oxford) 2012;51: 129-33.
47. Graf SW, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012;15: 102-9.
48. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010;6: 112-16.